bug Microsoft Fixes Exploited Privilege Escalation Flaw, 34 More Bugs By packetstormsecurity.com Published On :: Wed, 11 Dec 2019 16:44:06 GMT Full Article headline microsoft flaw patch
bug Intel Touts Bug Bounties To Hardware Hackers By packetstormsecurity.com Published On :: Fri, 17 Mar 2017 00:38:32 GMT Full Article headline hacker flaw mcafee
bug Google's Bug Bounty Program Just Had A Record-Breaking Year Of Payouts By packetstormsecurity.com Published On :: Wed, 29 Jan 2020 15:36:03 GMT Full Article headline hacker flaw google
bug Webex Bug Allowed Password Bypass By packetstormsecurity.com Published On :: Tue, 28 Jan 2020 15:39:43 GMT Full Article headline privacy flaw password cisco
bug Amadeus Airline Check-In Bug Exposed Boarding Passes By packetstormsecurity.com Published On :: Tue, 16 Jul 2019 13:53:49 GMT Full Article headline privacy data loss spyware terror
bug Bugs In Samsung IoT Hub Leave Smart Home Open To Attack By packetstormsecurity.com Published On :: Fri, 27 Jul 2018 15:01:12 GMT Full Article headline hacker flaw samsung
bug Samsung Bug Allows Any Fingerprint To Unlock Phones By packetstormsecurity.com Published On :: Fri, 18 Oct 2019 14:59:52 GMT Full Article headline phone flaw password samsung
bug Spec-Exec CPU Bugs Sweep Hacking Oscars By packetstormsecurity.com Published On :: Fri, 10 Aug 2018 16:07:55 GMT Full Article headline hacker flaw conference intel
bug Intel CMSE Bug Is Worse Than Previously Thought By packetstormsecurity.com Published On :: Thu, 05 Mar 2020 14:35:11 GMT Full Article headline flaw intel
bug Intel Fixes High-Severity Flaws In NUC, Discontinues Buggy Compute Module By packetstormsecurity.com Published On :: Wed, 15 Apr 2020 18:06:59 GMT Full Article headline flaw patch intel
bug New iOS Text Bomb Bug Can Crash Your iPhone By packetstormsecurity.com Published On :: Mon, 27 Apr 2020 14:34:04 GMT Full Article headline phone flaw apple
bug Linux/x64 Anti-Debug Trick INT3 Trap Shellcode By packetstormsecurity.com Published On :: Tue, 05 May 2020 21:01:22 GMT 113 bytes small Linux/x64 anti-debug trick (INT3 trap) with execve("/bin/sh") shellcode that is NULL free. Full Article
bug GitLab Awards Researcher $20,000 For Remote Code Execution Bug By packetstormsecurity.com Published On :: Wed, 29 Apr 2020 15:28:19 GMT Full Article headline hacker flaw patch
bug Oracle Warns Of Attacks Against Recently Patched WebLogic Security Bug By packetstormsecurity.com Published On :: Fri, 01 May 2020 13:36:40 GMT Full Article headline hacker flaw patch oracle
bug Google Pays $65k To Shutter 23 Chrome Bugs By packetstormsecurity.com Published On :: Mon, 30 May 2016 16:57:54 GMT Full Article headline flaw google chrome
bug Google Splats 21 Bugs In Chrome 54 Patch Run By packetstormsecurity.com Published On :: Fri, 14 Oct 2016 15:36:02 GMT Full Article headline flaw google patch chrome
bug Chrome On Windows Has Credential Theft Bug By packetstormsecurity.com Published On :: Wed, 17 May 2017 13:13:15 GMT Full Article headline flaw google password chrome
bug DigiCert Hit By Hackers Through Buggy Config Tool By packetstormsecurity.com Published On :: Tue, 05 May 2020 16:03:11 GMT Full Article headline hacker flaw password cryptography
bug Pwn2Own Contest Yields 13 Bugs, As Virtual Format Expands Talent Pool By packetstormsecurity.com Published On :: Mon, 23 Mar 2020 14:27:38 GMT Full Article headline hacker canada conference
bug Google Android RCE Bug Allows Attacker Full Device Access By packetstormsecurity.com Published On :: Tue, 05 May 2020 16:03:04 GMT Full Article headline privacy phone data loss flaw google
bug Random Number Bug Blights FreeBSD By packetstormsecurity.com Published On :: Fri, 30 Nov 2007 21:21:25 GMT Full Article bsd
bug FreeBSD Bug Grants Local Root Access By packetstormsecurity.com Published On :: Mon, 14 Sep 2009 02:07:55 GMT Full Article bsd
bug FreeBSD Bug Gives Untrusted Root Access By packetstormsecurity.com Published On :: Tue, 01 Dec 2009 21:02:11 GMT Full Article bsd
bug Whoops! Tiny Bug In NetBSD 6.0 Code Ruins SSH Crypto Keys By packetstormsecurity.com Published On :: Tue, 26 Mar 2013 15:15:25 GMT Full Article headline flaw bsd cryptography
bug Critical FreeBSD Bug Squashed By packetstormsecurity.com Published On :: Fri, 18 Mar 2016 15:38:27 GMT Full Article headline flaw bsd
bug X.org Bug Bites OpenBSD And Other Big Operating Systems By packetstormsecurity.com Published On :: Mon, 29 Oct 2018 14:37:28 GMT Full Article headline linux flaw bsd
bug Microsoft Warns Of Email Attacks Executing Code Using An Old Bug By packetstormsecurity.com Published On :: Tue, 11 Jun 2019 14:55:53 GMT Full Article headline malware microsoft email flaw
bug Love Bug's Creator Tracked Down To Repair Shop In Manila By packetstormsecurity.com Published On :: Mon, 04 May 2020 15:37:03 GMT Full Article headline malware email virus
bug Coronavirus: Facebook Blames Bug For Incorrectly Marked Spam By packetstormsecurity.com Published On :: Wed, 18 Mar 2020 14:37:52 GMT Full Article headline virus spam facebook
bug Nasty Security Bug Found And Fixed In Linux apt By packetstormsecurity.com Published On :: Wed, 23 Jan 2019 15:12:03 GMT Full Article headline linux flaw patch
bug Linux Command-Line Editors Vulnerable To High Severity Bug By packetstormsecurity.com Published On :: Wed, 12 Jun 2019 15:27:56 GMT Full Article headline linux flaw
bug Critical Linux Wi-Fi Bug Allows System Compromise By packetstormsecurity.com Published On :: Sat, 19 Oct 2019 15:36:59 GMT Full Article headline linux wireless flaw
bug Linux Bug Opens Most VPNs To Hijacking By packetstormsecurity.com Published On :: Mon, 09 Dec 2019 15:12:01 GMT Full Article headline hacker privacy linux flaw cryptography
bug New Remote Bug in OpenSSH v3.3 and Below By packetstormsecurity.com Published On :: Mon, 24 Jun 2002 08:34:07 GMT Full Article ssh
bug Remembering Saltergate: Fan who "caught the bug" in the 50s By article.wn.com Published On :: Sat, 09 May 2020 16:55 GMT Glenn Hutchinson has been in touch to tell us how his passion for the Spireites began when he visited Saltergate as a youngster in the mid-50s... I first visited the ground when I was about 7/8 in 1954/55 with my dad. Caught the bug and been a Spirerite ever since. When I was... Full Article
bug Lake Victoria forces out Bugonga dwellers By www.monitor.co.ug Published On :: 2020-05-09T09:28:06Z Since October last year, Lake Victoria has swallowed up to nearly 50 metres of the shoreline, leaving surrounding communities desperate Full Article
bug MPLAB PICkit4 In-Circuit Debugger User's Guide By ww1.microchip.com Published On :: 5/5/2020 2:06:35 PM MPLAB PICkit4 In-Circuit Debugger User's Guide Full Article
bug MPLAB PICkit 4 In-Circuit Debugger Quick Start Guide By ww1.microchip.com Published On :: 5/5/2020 2:52:35 PM MPLAB PICkit 4 In-Circuit Debugger Quick Start Guide Full Article
bug Bed Bugs Drawn to Red and Black Colors By www.medicinenet.com Published On :: Sat, 9 May 2020 00:00:00 PDT Title: Bed Bugs Drawn to Red and Black ColorsCategory: Health NewsCreated: 4/25/2016 12:00:00 AMLast Editorial Review: 4/26/2016 12:00:00 AM Full Article
bug Norovirus a Costly Bug By www.medicinenet.com Published On :: Sat, 9 May 2020 00:00:00 PDT Title: Norovirus a Costly BugCategory: Health NewsCreated: 4/26/2016 12:00:00 AMLast Editorial Review: 4/27/2016 12:00:00 AM Full Article
bug Day Care Babies Catch Stomach Bugs Earlier, But Get Fewer Later By www.medicinenet.com Published On :: Sat, 9 May 2020 00:00:00 PDT Title: Day Care Babies Catch Stomach Bugs Earlier, But Get Fewer LaterCategory: Health NewsCreated: 4/26/2016 12:00:00 AMLast Editorial Review: 4/27/2016 12:00:00 AM Full Article
bug Bedbugs (Bed Bugs) vs. Lice By www.medicinenet.com Published On :: Tue, 18 Feb 2020 00:00:00 PDT Title: Bedbugs (Bed Bugs) vs. LiceCategory: Diseases and ConditionsCreated: 2/18/2020 12:00:00 AMLast Editorial Review: 2/18/2020 12:00:00 AM Full Article
bug Insecticidal Activity of Doxycycline against the Common Bedbug [Experimental Therapeutics] By aac.asm.org Published On :: 2020-04-21T08:01:09-07:00 There is an ongoing need for safe and effective anti-bedbug compounds. Here, we tested the toxicity of three antimicrobial agents against bedbugs when administered orally. We reveal that doxycycline has direct insecticidal activity at 250 μg/ml (0.025%) that is particularly strong against immature bedbugs and appears to be independent of antimicrobial activity. Future studies to determine the mechanisms behind this property could be useful for the development of orally active insecticides or anti-bedbug therapeutics. Full Article
bug A lazy fix 20 years ago means the Y2K bug is taking down computers now By www.newscientist.com Published On :: Tue, 07 Jan 2020 13:32:02 +0000 The millennium bug is back with a vengeance, after programmers in the 1990s simply pushed the problem back by 20 years Full Article
bug COVIDSafe Still Has Bugs, According To Experts By feeds.gizmodo.com.au Published On :: Thu, 07 May 2020 13:45:11 +1000 There has been a lot of discussion surrounding the government's coronavirus tracing app, COVIDSafe, but at the forefront has been issues of privacy and its ability to work properly on devices. With the federal government tying the easing of social restrictions to app downloads, developers have reverse engineered the app to find out what's actually wrong with it. Here's what they've found. More ยป Full Article
bug Bug experts dismiss worry about U.S. 'murder hornets' as hype By www.ctvnews.ca Published On :: Thu, 7 May 2020 15:47:57 -0400 Insect experts say people should calm down about the big bug with the nickname "murder hornet" -- unless you are a beekeeper or a honeybee. Full Article
bug Washington state now has another bug to worry about after 'murder hornets' By www.ctvnews.ca Published On :: Fri, 8 May 2020 02:50:12 -0400 Washington state has another bug to worry about in addition to Asian giant hornets -- gypsy moths, which the state's governor says could become an "infestation." Full Article
bug Advancing antibiotic development in the age of 'superbugs' By webfeeds.brookings.edu Published On :: Fri, 27 Feb 2015 14:37:00 -0500 While antibiotics are necessary and crucial for treating bacterial infections, their misuse over time has contributed to a rather alarming rate of antibiotic resistance, including the development of multidrug-resistance bacteria or “super bugs.” Misuse manifests throughout all corners of public and private life; from the doctor’s office when prescribed to treat viruses; to industrial agriculture, where they are used in abundance to prevent disease in livestock. New data from the World Health Organization (WHO) and U.S. Centers for Disease Control and Prevention (CDC) confirm that rising overuse of antibiotics has already become a major public health threat worldwide. As drug resistance increases, we will see a number of dangerous and far-reaching consequences. First, common infections like STDs, pneumonia, and “staph” infections will become increasingly difficult to treat, and in extreme cases these infections may require hospitalization or treatment with expensive and toxic second-line therapies. In fact, recent estimates suggest that every year more than 23,000 people die due to drug-resistant infections in the U.S., and many more suffer from complications caused by resistant pathogens. Further, infections will be harder to control. Health care providers are increasingly encountering highly resistant infections not only in hospitals – where such infections can easily spread between vulnerable patients – but also in outpatient care settings. Fundamental Approaches to Slowing Resistance Incentivize appropriate use of antibiotics. Many patients and providers underestimate the risks of using antibiotics when they are not warranted, in part because these drugs often have rapid beneficial effects for those who truly need them. In many parts of the world the perception that antibiotics carry few risks has been bolstered by their low costs and availability without a prescription or contact with a trained health care provider. Education efforts, stewardship programs, and the development of new clinical guidelines have shown some success in limiting antibiotic use, but these fixes are limited in scope and generally not perceived as cost-effective or sustainable. Broader efforts to incentivize appropriate use, coupled with economic incentives, may be more effective in changing the culture of antibiotic use. These options might include physician or hospital report cards that help impact patient provider selection, or bonuses based on standardized performance measures that can be used to report on success of promoting appropriate use. While these might create additional costs, they would likely help control rates of drug resistant infections and outweigh the costs of treating them. Reinvigorate the drug development pipeline with novel antibiotics. There has not been a new class of antibiotics discovered in almost three decades, and companies have largely left the infectious disease space for more stable and lucrative product lines, such as cancer and chronic disease. Antibiotics have historically been inexpensive and are typically used only for short periods of time, creating limited opportunities for return on investment. In addition, unlike cancer or heart disease treatments, antibiotics lose effectiveness over time, making them unattractive for investment. Once they are on the market, the push to limit use of certain antibiotics to the most severe infections can further constrict an already weak market. Late last year, H.R. 3742, the Antibiotic Development to Advance Patient Treatment (ADAPT) Act of 2013, was introduced and referred to the House Energy and Commerce Subcommittee on Health. If enacted, the ADAPT Act would create a streamlined development pathway to expedite the approval of antibiotics that treat limited patient populations with serious unmet medical needs. This could potentially reduce costs and development time for companies, thereby encouraging investment in this space. Regulators have indicated that they would also welcome the opportunity to evaluate benefits and risk for a more selective patient subpopulation if they could be confident the product would be used appropriately. The bill has received a great deal of support and would help address a critical public health need (I cover this topic in more detail with my colleagues Kevin Outterson, John Powers, and Mark McClellan in a recent Health Affairs paper). Advance new economic incentives to remedy market failure. Innovative changes to pharmaceutical regulation, research and development (R&D), and reimbursement are necessary to alleviate the market failure for antibacterial drugs. A major challenge, particularly within a fee-for-service or volume-based reimbursement system, is providing economic incentives that promote investment in drug development without encouraging overuse. A number of public and private stakeholders, including the Engelberg Center for Health Care Reform and Chatham House’s Centre on Global Health Security Working Group on Antimicrobial Resistance, are exploring alternative reimbursement mechanisms that “de-link” revenue from the volume of antibiotics sold. Such a mechanism, combined with further measures to stimulate innovation, could create a stable incentive structure to support R&D. Improve tracking and monitoring of resistance in the outpatient setting. There is increasing concern about much less rigorous surveillance capabilities in the outpatient setting, where drug-resistant infections are also on the rise. Policymakers should consider new incentives for providers and insurers to encourage a coordinated approach for tracking inpatient and outpatient resistance data. The ADAPT Act, mentioned above, also seeks to enhance monitoring of antibiotic utilization and resistance patterns. Health insurance companies can leverage resistance-related data linked to health care claims, while providers can capture lab results in electronic health records. Ultimately, this data could be linked to health and economic outcomes at the state, federal, and international levels, and provide a more comprehensive population-based understanding of the impact and spread of resistance. Current examples include the Food and Drug Administration’s (FDA) Sentinel Initiative and the Patient-Centered Outcomes Research Institute’s PCORnet initiative. Antibiotic resistance is an urgent and persistent threat. As such, patients and providers will continue to require new antibiotics as older drugs are forced into retirement by resistant pathogens. Stewardship efforts will remain critical in the absence of game-changing therapies that parry resistance mechanisms. Lastly, a coordinated surveillance approach that involves diverse stakeholder groups is needed to understand the health and economic consequences of drug resistance, and to inform antibiotic development and stewardship efforts. Editor's note: This blog was originally posted in May 2014 on Brookings UpFront. Authors Gregory W. Daniel Full Article
bug Advancing antibiotic development in the age of 'superbugs' By webfeeds.brookings.edu Published On :: Fri, 27 Feb 2015 14:37:00 -0500 While antibiotics are necessary and crucial for treating bacterial infections, their misuse over time has contributed to a rather alarming rate of antibiotic resistance, including the development of multidrug-resistance bacteria or “super bugs.” Misuse manifests throughout all corners of public and private life; from the doctor’s office when prescribed to treat viruses; to industrial agriculture, where they are used in abundance to prevent disease in livestock. New data from the World Health Organization (WHO) and U.S. Centers for Disease Control and Prevention (CDC) confirm that rising overuse of antibiotics has already become a major public health threat worldwide. As drug resistance increases, we will see a number of dangerous and far-reaching consequences. First, common infections like STDs, pneumonia, and “staph” infections will become increasingly difficult to treat, and in extreme cases these infections may require hospitalization or treatment with expensive and toxic second-line therapies. In fact, recent estimates suggest that every year more than 23,000 people die due to drug-resistant infections in the U.S., and many more suffer from complications caused by resistant pathogens. Further, infections will be harder to control. Health care providers are increasingly encountering highly resistant infections not only in hospitals – where such infections can easily spread between vulnerable patients – but also in outpatient care settings. Fundamental Approaches to Slowing Resistance Incentivize appropriate use of antibiotics. Many patients and providers underestimate the risks of using antibiotics when they are not warranted, in part because these drugs often have rapid beneficial effects for those who truly need them. In many parts of the world the perception that antibiotics carry few risks has been bolstered by their low costs and availability without a prescription or contact with a trained health care provider. Education efforts, stewardship programs, and the development of new clinical guidelines have shown some success in limiting antibiotic use, but these fixes are limited in scope and generally not perceived as cost-effective or sustainable. Broader efforts to incentivize appropriate use, coupled with economic incentives, may be more effective in changing the culture of antibiotic use. These options might include physician or hospital report cards that help impact patient provider selection, or bonuses based on standardized performance measures that can be used to report on success of promoting appropriate use. While these might create additional costs, they would likely help control rates of drug resistant infections and outweigh the costs of treating them. Reinvigorate the drug development pipeline with novel antibiotics. There has not been a new class of antibiotics discovered in almost three decades, and companies have largely left the infectious disease space for more stable and lucrative product lines, such as cancer and chronic disease. Antibiotics have historically been inexpensive and are typically used only for short periods of time, creating limited opportunities for return on investment. In addition, unlike cancer or heart disease treatments, antibiotics lose effectiveness over time, making them unattractive for investment. Once they are on the market, the push to limit use of certain antibiotics to the most severe infections can further constrict an already weak market. Late last year, H.R. 3742, the Antibiotic Development to Advance Patient Treatment (ADAPT) Act of 2013, was introduced and referred to the House Energy and Commerce Subcommittee on Health. If enacted, the ADAPT Act would create a streamlined development pathway to expedite the approval of antibiotics that treat limited patient populations with serious unmet medical needs. This could potentially reduce costs and development time for companies, thereby encouraging investment in this space. Regulators have indicated that they would also welcome the opportunity to evaluate benefits and risk for a more selective patient subpopulation if they could be confident the product would be used appropriately. The bill has received a great deal of support and would help address a critical public health need (I cover this topic in more detail with my colleagues Kevin Outterson, John Powers, and Mark McClellan in a recent Health Affairs paper). Advance new economic incentives to remedy market failure. Innovative changes to pharmaceutical regulation, research and development (R&D), and reimbursement are necessary to alleviate the market failure for antibacterial drugs. A major challenge, particularly within a fee-for-service or volume-based reimbursement system, is providing economic incentives that promote investment in drug development without encouraging overuse. A number of public and private stakeholders, including the Engelberg Center for Health Care Reform and Chatham House’s Centre on Global Health Security Working Group on Antimicrobial Resistance, are exploring alternative reimbursement mechanisms that “de-link” revenue from the volume of antibiotics sold. Such a mechanism, combined with further measures to stimulate innovation, could create a stable incentive structure to support R&D. Improve tracking and monitoring of resistance in the outpatient setting. There is increasing concern about much less rigorous surveillance capabilities in the outpatient setting, where drug-resistant infections are also on the rise. Policymakers should consider new incentives for providers and insurers to encourage a coordinated approach for tracking inpatient and outpatient resistance data. The ADAPT Act, mentioned above, also seeks to enhance monitoring of antibiotic utilization and resistance patterns. Health insurance companies can leverage resistance-related data linked to health care claims, while providers can capture lab results in electronic health records. Ultimately, this data could be linked to health and economic outcomes at the state, federal, and international levels, and provide a more comprehensive population-based understanding of the impact and spread of resistance. Current examples include the Food and Drug Administration’s (FDA) Sentinel Initiative and the Patient-Centered Outcomes Research Institute’s PCORnet initiative. Antibiotic resistance is an urgent and persistent threat. As such, patients and providers will continue to require new antibiotics as older drugs are forced into retirement by resistant pathogens. Stewardship efforts will remain critical in the absence of game-changing therapies that parry resistance mechanisms. Lastly, a coordinated surveillance approach that involves diverse stakeholder groups is needed to understand the health and economic consequences of drug resistance, and to inform antibiotic development and stewardship efforts. Editor's note: This blog was originally posted in May 2014 on Brookings UpFront. Authors Gregory W. Daniel Full Article
bug This song bugged me for 15 years. So I tracked down the songwriter. By www.treehugger.com Published On :: Mon, 11 Jun 2018 07:30:00 -0400 Spoiler alert: The writer turned out to be a YouTube star. Full Article Living